An update from KDIGO, an independent organization that aims to improve the care of patients with kidney disease worldwide. A layered approach is recommended while caring for patients with diabetes and ...

Please provide your email address to receive an email when new articles are posted on . The Kidney Disease Improving Global Outcomes updated the clinical practice guidelines for treating patients with ...

Finerenone use for 6 months was safe and associated with a significant 25% decrease in albuminuria for adults with type 1 diabetes and chronic kidney disease, according to data presented in the ...

In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...

In a recent study published in Kidney International Reports, researchers investigated the effects of semaglutide (administered once weekly) on kidney disease outcomes and changes in KDIGO (short for ...

LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO ...

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a new ...

Hydration is a surprisingly important diabetes health factor, and its even more important if you also have chronic kidney disease (CKD). CKD develops in 10 to 40 percent of people with type 2 diabetes ...

The impact of chronic kidney disease (CKD) on patients and the health care system in the United States is substantial and expected to increase with the expanding obesity-driven diabetes epidemic. 1 ...